Cost of Revenues: Cost of revenues for the third quarter of fiscal 2022 was $31.0 million compared to $20.9 million for the same period of fiscal 2021.Revenue: Total revenues for the third quarter of fiscal 2022 were $56.1 million compared to $35.0 million for the same period of fiscal 2021.Orders: Total orders received for the third quarter of fiscal 2022 were $59.7 million compared to $39.1 million for the same period of fiscal 2021.We are well positioned to take market share in synbio and NGS, deliver new antibody targets for our biopharma customers and advance our efforts in DNA data storage toward our first commercial solution, all while targeting toward adjusted EBITDA breakeven at $300 million annual revenue for the core business."įISCAL 2022 THIRD QUARTER FINANCIAL RESULTS Leproust continued, "Moving forward, we plan to launch the Factory of the Future in January 2023, which will facilitate growth across all areas of our business. #TWIST BIOSCIENCE LICENSE#We entered into our first exclusive option and license agreement for a Twist-discovered antibody and continue to build a robust ecosystem for DNA data storage through educational materials, including the most recently published white paper, and by driving toward an interoperable system through the development of industry standards."ĭr. “We continue to see large accounts expanding their footprint while we also focus on diversifying our risk across an increasing number of customers, particularly in biopharma. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We are the high quality, low cost leader and as the macroeconomic environment continues to hold uncertainty, Twist’s product offerings are resonating with customers,” said Emily M. – Oligos Pool, e.g.SOUTH SAN FRANCISCO, Calif.-( BUSINESS WIRE)- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2022 ended June 30, 2022. – Quality and quantity of our synthetic biology tools help researchers rapidly realize opportunities ahead – Platform technology overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis – Innovative silicon-based DNA Synthesis Platform enables production of high-quality synthetic DNA faster and more affordable than ever before. Traditional synthesis methods produce a single gene in the same physical space using a 96-well plate. #TWIST BIOSCIENCE FULL#This miniaturization allows us to reduce the reaction volumes by a factor of 1,000,000 while increasing throughput by a factor of 1,000, enabling the synthesis of 9,600 genes on a single silicon chip at full scale. Twist Bioscience developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high-throughput silicon platform that allows us to miniaturize the chemistry necessary for DNA synthesis. TWIST have industrialized the production of cost-effective, high-fidelity, high-throughput DNA, which is delivered to our customers via seamless Online Ordering. Applying rigorous engineering principles to harness the highly-scalable production and processing infrastructure of the semiconductor industry allows us to achieve precision in manufacturing DNA at scale. Twist Bioscience developed the DNA Synthesis Platform to address the limitations of throughput, scalability and cost inherent in legacy DNA synthesis methods. TWIST Bioscience created a revolutionary silicon-based DNA synthesis platform, that offers precision at a scale otherwise unavailable to our customers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |